Face-washing behavior induced by the group I metabotropic glutamate receptor agonist (S)-3,5-DHPG in mice is mediated by mGlu1 receptor.

[1]  Hisashi Ohta,et al.  Pharmacological Characterization of a New, Orally Active and Potent Allosteric Metabotropic Glutamate Receptor 1 Antagonist, 4-[1-(2-Fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC) , 2007, Journal of Pharmacology and Experimental Therapeutics.

[2]  M. Barton,et al.  Behavioral and convulsant effects of the (S) enantiomer of the group I metabotropic glutamate receptor agonist 3,5-DHPG in mice , 2005, Neuropharmacology.

[3]  H. Car,et al.  Influence of AIDA on certain behaviors in rats subjected to experimental hypoxia. , 2003, Polish journal of pharmacology.

[4]  D. Schoepp,et al.  Inhibition of group I metabotropic glutamate receptor responses in vivo in rats by a new generation of carboxyphenylglycine-like amino acid antagonists , 2002, Neuroscience Letters.

[5]  W. Löscher,et al.  In vivo pharmacology of BIIR 561 CL, a novel combined antagonist of AMPA receptors and voltage‐dependent Na+ channels , 2001, British journal of pharmacology.

[6]  W. Spooren,et al.  Novel allosteric antagonists shed light on mglu(5) receptors and CNS disorders. , 2001, Trends in pharmacological sciences.

[7]  H. Car,et al.  NMDA receptor antagonists change behavioral activity of rats treated with (S)-4CPG. , 2001, Polish journal of pharmacology.

[8]  B. Meldrum,et al.  Anti-epileptic activity of group II metabotropic glutamate receptor agonists (−)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY379268) and (−)-2-thia-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY389795) , 2001, Neuropharmacology.

[9]  B. Meldrum,et al.  Anticonvulsant activity of two metabotropic glutamate Group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893) , 2000, Neuropharmacology.

[10]  B. Meldrum,et al.  Glutamate as a neurotransmitter in the brain: review of physiology and pathology. , 2000, The Journal of nutrition.

[11]  D. Jane,et al.  Pharmacological agents acting at subtypes of metabotropic glutamate receptors , 1999, Neuropharmacology.

[12]  F. Bordi,et al.  Group I metabotropic glutamate receptors: implications for brain diseases , 1999, Progress in Neurobiology.

[13]  N. O. Dalby,et al.  Roles of metabotropic glutamate receptor subtypes in modulation of pentylenetetrazole-induced seizure activity in mice , 1998, Neuropharmacology.

[14]  J. Bockaert,et al.  Phenylglycine derivatives discriminate between mGluR1- and mGluR5-mediated responses , 1995, Neuropharmacology.

[15]  D. Schoepp,et al.  Induction or protection of limbic seizures in mice by mGluR subtype selective agonists , 1995, Neuropharmacology.

[16]  D. Schoepp,et al.  Enzymatic resolution and pharmacological activity of the enantiomers of 3,5-dihydroxyphenylglycine, a metabotropic glutamate receptor agonist , 1995 .

[17]  R. Duvoisin,et al.  The metabotropic glutamate receptors: Structure and functions , 1995, Neuropharmacology.

[18]  H. Klitgaard,et al.  Metabotropic and ionotropic excitatory amino acid receptor agonists induce different behavioral effects in mice. , 1993, European journal of pharmacology.

[19]  D. Schoepp,et al.  Intracerebral 1S,3R-1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD) produces limbic seizures that are not blocked by ionotropic glutamate receptor antagonists , 1993, Neuroscience Letters.

[20]  J. Pin,et al.  Pharmacology and functions of metabotropic glutamate receptors. , 1997, Annual review of pharmacology and toxicology.

[21]  S. Nakanishi,et al.  Molecular diversity and functions of glutamate receptors. , 1994, Annual review of biophysics and biomolecular structure.